1. Home
  2. Protocols and Guidelines
  3. Current CAP Guidelines
  4. Human Papillomavirus Testing in Head and Neck Carcinomas

Human Papillomavirus Testing in Head and Neck Carcinomas

Background

Our evidence-based, clinical practice guideline “Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas” helps to standardize testing for HPV in head and neck carcinomas. It recommends that all patients with newly diagnosed oropharyngeal squamous cell carcinoma be tested for high-risk HPV. 

The guideline was developed by our Pathology and Laboratory Quality Center of Evidence-based Guidelines and its interdisciplinary, expert panel of surgical and molecular pathologists, cytopathologists, head and neck surgeons, and radiation and medical oncologists. The panel screened more than 2,200 articles and reviewed evidence from 492 studies to develop a total of 14 guideline recommendations.

Clinical teams should adopt the guideline, available in the Archives of Pathology & Laboratory Medicine, to ensure eligible patients receive consistent, accurate assessment of HPV status.

Guideline Information

  • Status: Active
  • Published online ahead of print: December 18, 2017
  • Originally published: May 2018

Guideline Tools and Resources

Download the following tools and resources to help implement the guideline:

Have a Question or Comment?

Send us an email.

Email the Center Right Arrow